State of Wyoming Purchases 80,638 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

State of Wyoming acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 80,638 shares of the biotechnology company’s stock, valued at approximately $672,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BCRX. Nykredit A S bought a new position in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $27,000. IFP Advisors Inc grew its position in BioCryst Pharmaceuticals by 2,515.3% in the 2nd quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 3,119 shares during the last quarter. Allworth Financial LP acquired a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $52,000. Pallas Capital Advisors LLC bought a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at about $101,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter worth about $103,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $8.47 on Monday. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.23 and a 52-week high of $11.22. The firm has a market capitalization of $2.16 billion, a PE ratio of -5.65 and a beta of 0.55. The company’s fifty day moving average price is $8.63 and its two-hundred day moving average price is $8.72.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. During the same quarter in the prior year, the firm earned $0.15 EPS. The firm’s quarterly revenue was up 33.6% compared to the same quarter last year. Analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BCRX. JPMorgan Chase & Co. raised their price objective on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Wednesday, September 30th. Wedbush reduced their price objective on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 8th. Royal Bank Of Canada cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $13.00 to $11.00 in a report on Thursday, September 10th. Finally, Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 24th. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $19.44.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.